David E. Bloom (
Daniel Cadarette is a research and communications manager in the Department of Global Health and Population at the Harvard T. H. Chan School of Public Health.
Health Aff (Millwood). 2021 Mar;40(3):410-418. doi: 10.1377/hlthaff.2020.02012. Epub 2021 Feb 4.
Coronavirus disease 2019 (COVID-19) vaccine development and manufacturing have proceeded at a historically unprecedented pace. This speed may be accounted for by the unprecedented scale of resources being devoted to addressing COVID-19; an unusual intensity of cooperation, encompassing the public and private sectors and occurring both within and across national borders; and innovation with respect to both technologies (for example, new vaccine platforms) and processes (for example, vaccine clinical trials). In this article we describe and analyze how resources, cooperation, and innovation have contributed to the accelerated development of COVID-19 vaccines. Similar levels and types of public investment, models of cooperation, and harnessing of innovative processes and technologies could be applied to future epidemics and other global health challenges.
2019 年冠状病毒病（COVID-19）疫苗的开发和制造以前所未有的速度推进。这种速度可以归因于前所未有的资源投入规模，用于应对 COVID-19；公共和私营部门之间空前的合作程度，包括在国内外的合作；以及技术（例如新型疫苗平台）和流程（例如疫苗临床试验）的创新。在本文中，我们描述和分析了资源、合作和创新如何促进 COVID-19 疫苗的加速开发。类似水平和类型的公共投资、合作模式以及利用创新流程和技术可以应用于未来的传染病和其他全球卫生挑战。
